Abstract 290P
Background
Renal cell carcinoma(RCC) constitutes a broad spectrum of aggressiveness with variable outcomes depending on existing risk factors. 20% patients present with de novo metastasis and almost 30% progress distantly after the treatment of primary. Management options of metastatic RCC include Active surveillance, Surgery (Cytoreductive nephrectomy/ metastasectomy), Local ablative therapy(SBRT) and systemic therapy. Recently SBRT has emerged as promising therapy for both primary and metastatic sites with favorable local control and toxicity rates. SBRT can be delivered upfront to delay systemic therapy or sequentially with systemic therapy. In our study, we analyzed 40 patients diagnosed with metastatic RCC, treated with SBRT with respect to disease control and survival outcomes.
Methods
40 patients diagnosed with biopsy proven metastatic RCC with ECOG Performance status
Results
40 patients (M:F - 29:11) with a median age of 45 years (Age range- 35 to 80 years) were included in the study. SBRT was delivered to metastatic sites in the Brain (37.5%), Kidney (40%), Adrenal (12.5%), Lung (22.5%), Bone (40%), Liver (17.5%), Lymph node (10%). Median Overall Survival was observed to be 24 months and median Progression Free Survival was 18 months.
Conclusions
SBRT is well tolerated in patients with metastatic RCC and has a significant impact in disease control translating to improved Overall Survival. In the era of high precision oncology, SBRT should be considered as an integral component for the treatment of Metastatic RCC.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
S.P. Susheela.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.